Hematologic Malignancy
Mature B-Cell Neoplasm
CI-CAN-00003258Explore in graph →
HematologicNon-malignant1,787 active trials44 approved drugs119 evidence items
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003258Explore in graph →
Clinical trials
6,664 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07735533 | A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies | not yet recruiting | Phase 1 / Phase 2 | 274 | Umoja BiopharmaINDUSTRY | 0 | Aug 17, 2026 | clinicaltrials |
| NCT07735546 | A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma | not yet recruiting | Phase 1 | 100 | Umoja BiopharmaINDUSTRY | 0 | Aug 17, 2026 | clinicaltrials |
| NCT07662928 |
| Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study |
| not yet recruiting |
| Phase 2 |
| 43 |
| AIDS Malignancy ConsortiumNETWORK |
| 1 |
| Aug 14, 2026 |
| clinicaltrials |
| NCT07764601 | R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma(RM-MA-PD1) | not yet recruiting | N/A | 58 | WEI XUOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07764861 | A Open-Label Phase in Participants With Multiple Myeloma | not yet recruiting | Phase 2 | 120 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07766421 | Evaluation of Iopofosine I 131 vs. R-CD in WM Patients | not yet recruiting | Phase 3 | 219 | Cellectar Biosciences, Inc.INDUSTRY | 0 | Aug 14, 2026 | clinicaltrials |
| NCT07649304 | AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") | not yet recruiting | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 0 | Aug 13, 2026 | clinicaltrials |
| NCT07759661 | Innovative 3D Preclinical Models for Mature B-cell Malignancies to Advance Personalized Immuno and Combination Therapies(IMPACT) | not yet recruiting | — | 64 | IRCCS San RaffaeleOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07759102 | Allogeneic ORCA-Q Stem Cell Transplant for the Treatment of Relapsed and Refractory High Risk Multiple Myeloma | not yet recruiting | Phase 1 | 20 | University of California, DavisOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07760610 | Pomalidomide Plus Rituximab Maintenance in Young High-Risk Newly Diagnosed DLBCL After First-Line Response | not yet recruiting | Phase 4 | 27 | The First Hospital of Jilin UniversityOTHER | 0 | Aug 12, 2026 | clinicaltrials |
| NCT07757412 | Teclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple Myeloma.(ADAPTATION) | not yet recruiting | Phase 2 | 50 | Odense University HospitalOTHER | 4 | Aug 11, 2026 | clinicaltrials |
| NCT07009899 | BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM)(RECLAIM) | not yet recruiting | Phase 2 | 34 | Medical College of WisconsinOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07221032 | FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma | not yet recruiting | Phase 1 | 12 | Medical College of WisconsinOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07751471 | BCMA/GPRC5D Trispecific Antibody Treatment for Newly Diagnosed Amyloidosis (AL-004)(AL-004) | not yet recruiting | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07744750 | Pirtobrutinib+Sonrotoclax(PS) Regimen in the Treatment of B-Cell Lymphoma | not yet recruiting | Phase 2 | 40 | Changzhou No.2 People's HospitalOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07748689 | Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.(REBEL) | not yet recruiting | Phase 2 | 228 | Polish Myeloma ConsortiumOTHER | 0 | Aug 6, 2026 | clinicaltrials |
| NCT07749976 | GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 108 | VitruviaeINDUSTRY | 0 | Aug 6, 2026 | clinicaltrials |
| NCT07526597 | Study on Treatment Outcome Patterns for Patients With CLL After Discontinuation of BTK Inhibitors(STOP-CLL-DCT) | not yet recruiting | Phase 2 | 45 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07712588 | Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19) | not yet recruiting | Phase 2 / Phase 3 | 880 | Dizal PharmaceuticalsINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07741695 | Targeting IRAK4 in Chronic Lymphocytic Leukemia(PS-CLL016) | not yet recruiting | — | 50 | IRCCS San RaffaeleOTHER | 0 | Aug 4, 2026 | clinicaltrials |
| NCT07742527 | A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of Care(DynaMMic-2) | not yet recruiting | Phase 1 | 22 | GlaxoSmithKlineINDUSTRY | 0 | Aug 3, 2026 | clinicaltrials |
| NCT07738887 | Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations(EVITA) | not yet recruiting | Phase 2 | 44 | The Lymphoma Academic Research OrganisationOTHER | 2 | Jul 31, 2026 | clinicaltrials |
| NCT07740486 | A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable Disease(TiTan) | not yet recruiting | Phase 3 | 248 | Polish Myeloma ConsortiumOTHER | 0 | Jul 31, 2026 | clinicaltrials |
| NCT07735637 | A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).(DURGA-6) | not yet recruiting | Phase 3 | 750 | AstraZenecaINDUSTRY | 15 | Jul 30, 2026 | clinicaltrials |
| NCT07459608 | Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Mature B-cell Lymphoma | not yet recruiting | Phase 2 | 75 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07732712 | Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells | not yet recruiting | Phase 2 / Phase 3 | 15 | The Affiliated People's Hospital of Ningbo UniversityOTHER_GOV | 0 | Jul 29, 2026 | clinicaltrials |
| NCT07727668 | Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM) | not yet recruiting | Early Phase 1 | 22 | Shambavi RichardOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07728188 | A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma | not yet recruiting | Phase 3 | 520 | AbbVieINDUSTRY | 13 | Jul 27, 2026 | clinicaltrials |
| NCT07729397 | Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)(ANCILE-30) | not yet recruiting | Phase 1 | 21 | The Methodist Hospital Research InstituteOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07725406 | Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma(Prime REMIX) | not yet recruiting | Phase 1 | 32 | Weill Medical College of Cornell UniversityOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07726160 | A Study of KIV-318 Injection in Patients With BCMA-Positive Relapsed/Refractory Multiple Myeloma(KIV-318) | not yet recruiting | Phase 1 | 30 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07719855 | A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma | not yet recruiting | Phase 3 | 652 | Ruijin HospitalOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07720843 | TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM)(TaBleMM) | not yet recruiting | Phase 1 | 50 | Montefiore Medical CenterOTHER | 0 | Jul 22, 2026 | clinicaltrials |
| NCT07713459 | A Phase II Study to Evaluate the Efficacy of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas | not yet recruiting | Phase 2 | 105 | Kure Cells, INCINDUSTRY | 0 | Jul 20, 2026 | clinicaltrials |
| NCT07713511 | INfections in Patients Treated With CAR-T(IN-CART) | not yet recruiting | — | 290 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07714421 | Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients | not yet recruiting | Phase 1 | 20 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07709884 | A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Multiple Myeloma Patients With t(11;14) Suitable for Transplantation Using the SonKRd Regimen | not yet recruiting | Phase 4 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07711327 | Atrial Fibrillation Among Patients With Hematologic Malignancies on Tyrosine Kinase Inhibitor Therapy | not yet recruiting | — | 500 | Tina BaykanerOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07705308 | A Prospective Study of Response-adapted Low-dose Radiotherapy Combined With Orelabrutinib for Localized Mucosa-associated Lymphoid Tissue Extranodal Marginal Zone Lymphoma | not yet recruiting | Phase 2 | 140 | Ruijin HospitalOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07702851 | A Study of Polatuzumab Vedotin and Glofitamab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Within 12 Months After R-CHOP | not yet recruiting | Phase 2 | 47 | Yonsei UniversityOTHER | 0 | Jul 14, 2026 | clinicaltrials |
| NCT07599423 | A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | not yet recruiting | Phase 2 | 96 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07638722 | Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment | not yet recruiting | Phase 2 | 138 | SWOG Cancer Research NetworkNETWORK | 0 | Jul 13, 2026 | clinicaltrials |
| NCT07697339 | HDM2005 Combination Therapy in Relapsed/Refractory Mantle Cell Lymphoma | not yet recruiting | Phase 1 | 40 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 0 | Jul 13, 2026 | clinicaltrials |
| NCT07695740 | Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma | not yet recruiting | Phase 2 | 64 | Excyte Biopharma LtdINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07420959 | ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia | not yet recruiting | Phase 1 / Phase 2 | 38 | Mayo ClinicOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07690891 | Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia | not yet recruiting | Phase 2 | 30 | Medical College of WisconsinOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07691034 | Monitoring MRD in Multiple Myeloma in Serum by Mass Spectrometry | not yet recruiting | — | 40 | Odense University HospitalOTHER | 0 | Jul 8, 2026 | clinicaltrials |
| NCT07687004 | Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification(AL-005) | not yet recruiting | Phase 1 / Phase 2 | 50 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07684274 | Early Screening for Multiple Myeloma Based on Liquid Biopsy cfDNA Fragmentomics | not yet recruiting | — | 290 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Jul 6, 2026 | clinicaltrials |
| NCT07684950 | Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapy | not yet recruiting | Phase 2 | 45 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 6, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 17, 2026source: clinicaltrials